Microglial TREM2 state determines whether C1q-tagged substrates are cleared adaptively or converted into chronic complement-associated synaptotoxic inflammation
The debate revealed fundamental disagreement about whether C1q has spatially distinct functions at synapses versus microglia, or whether outcomes depend solely on binding partners. This mechanistic uncertainty undermines all proposed therapeutic strategies targeting C1q.
Source: Debate session sess_SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1 (Analysis: SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1)
This hypothesis reconciles conflicting C1q phenotypes by placing receiver-cell state downstream of a common upstream C1q-tagging event. In a competent TREM2 program, microglia clear tagged material efficiently; in TREM2-impaired states, the same substrates persist, amplifying complement and bystander synapse loss.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["C1Q Deficiency Impaired Clearance of Apoptotic Cells"]
B["C1QC Assembly Heterocomplex Formation"]
C["Synaptic Pruning Dysregulation Unpruned Connections"]
D["Microglial Overactivation Complement Deposition"]
E["C3b/C4b Deposition Neuronal Surface"]
F["Synaptic Loss Excessive Pruning in AD"]
G["Long-Term Potentiation Memory Formation Impaired"]
H["Cognitive Decline AD-Related Dementia"]
A --> B
B --> C
B --> D
C --> F
D --> E
E --> F
F --> G
G --> H
style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
9 citations9 with PMID5 mediumValidation: 0%7 supporting / 2 opposing
✓For(7)
5
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
7
2
MECH 7CLIN 0GENE 2EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
TREM2 drives microglia response to amyloid-β via S…
Microglial state is a major determinant of neurodegenerative response programs, making it plausible that ident…▼
Microglial state is a major determinant of neurodegenerative response programs, making it plausible that identical opsonized substrates can lead to different outcomes.
TREM2 biology is pleiotropic, and observed effects may reflect broader changes in metabolism, clustering, or p…▼
TREM2 biology is pleiotropic, and observed effects may reflect broader changes in metabolism, clustering, or plaque handling rather than a specific C1q decision node.
The claim that TREM2 state alone determines adaptive versus toxic handling likely overstates causality because…▼
The claim that TREM2 state alone determines adaptive versus toxic handling likely overstates causality because astrocytes, other receptors, and complement regulators also shape outcome.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-25 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Synaptic C1q drives complement-dependent pruning, while microglial surface-associated C1q biases phagocyte state through receptor-specific signaling
Mechanism: C1q deposited on weak or stressed synapses preferentially nucleates the classical complement cascade (`C1q -> C4 -> C3`), generating opsonins that engage microglial CR3/ITGAM-ITGB2 and promote engulfment. In contrast, C1q bound directly to microglial receptors or pericellular ligands may alter microglial transcriptional state without requiring full downstream complement activation. This would make localization mechanis
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Overall skeptical read: the debate is probably mixing three separable variables that have not been cleanly orthogonalized experimentally: `location`, `ligand identity`, and `receiver-cell state`. The strongest evidence supports synaptic C1q/C3/CR3-mediated pruning in development and AD models, but that does not by itself prove a distinct microglial surface-signaling program for C1q, nor a binding-partner hierarchy that dominates location. Much of the translational logic is still mouse-heavy and disease-model dependent. Key anchors: synaptic pruning by C1q/C3 in development ([PMID: 18083105](ht
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Triage
The ideas worth carrying forward are `6`, `5`, `1`, `2`, `4`, and `7`, in that order. I would drop `3` for now; it is too speculative to support a drug program.
The main translational point is that only one of these is close to a druggable thesis today: `block classical-pathway activation downstream of C1q` rather than trying to solve all C1q biology first. The rest are mostly mechanism, stratification, or endpoint-selection hypotheses.
Feasibility: Highest. This is the cleanest therapeutic hypothesis becaus
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[{"title":"Selective blockade of classical-pathway activation downstream of C1q will reduce synaptotoxic complement amplification while preserving beneficial C1q recognition functions","description":"The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway protease activity than on C1q recognition alone. In this model, inhibiting C1r/C1s should attenuate C4/C3-mediated synapse loss and neuroinflammation while preserving some homeostatic debris sensing and cargo recognition by C1q.","target_gene":"C1QA,C1QB,C1QC
IF TREM2 signaling is activated pharmacologically (using agonistic antibody clone 5F12 at 10 mg/kg, i.p., 3x/week for 4 weeks) in 12-month-old TREM2-WT mice with established C1q-bound synaptic debris, THEN microglial phagocytosis of C1q+ synaptic material will increase by ≥40% (measured by Iba1+C1q+Synapsin+ colocalization per 100 µm² cortical tissue) compared to isotype-treated controls within 14 days of treatment initiation.
pendingconf: 0.65
Expected outcome: ≥40% increase in microglial engulfment of C1q-tagged synaptic elements, quantified as Iba1+ cells containing ≥3 C1q+Synapsin+ puncta
Falsified by: No statistically significant increase in C1q+ synaptic debris clearance (p>0.05, Mann-Whitney U test) in TREM2-agonist treated vs. control groups; clearance remains <20% above baseline
Method: C57BL/6J female mice (n≥12/group), stereotactic injection of purified human C1q (2 µg/side) into medial prefrontal cortex to tag endogenous synapses, followed by TREM2 agonistic antibody or isotype control treatment; endpoint analysis by confocal microscopy with stereological sampling of injection sites
IF TREM2 is genetically ablated (TREM2-KO) in 5xFAD amyloid model mice, THEN cortical synaptosomal C3 protein levels will increase by ≥2.5-fold at 6 months of age compared to TREM2-WT 5xFAD controls, with corresponding increases in C1QA, C1QB, and C1QC subunits.
pendingconf: 0.55
Expected outcome: ≥2.5-fold increase in C3 concentration (ng/mg synaptosomal protein) and ≥1.8-fold increase in C1q subunits in TREM2-KO vs. TREM2-WT 5xFAD mice
Falsified by: No significant elevation (fold-change <1.3) of C3 or C1q proteins in TREM2-KO synaptosomes; complement levels remain equivalent to or below TREM2-WT levels
Method: 5xFAD;TREM2-KO and 5xFAD;TREM2-WT littermate mice (n≥10/genotype, equal sex distribution), synaptosome preparation from bilateral cortical tissue at 6 months via discontinuous sucrose gradient, quantitative Western blot normalized to β-actin and Synapsin-1, ELISA validation for absolute protein concentrations